Page 76 - Read Online

Fraser. J Transl Genet Genom 2018;2:21. I https://doi.org/10.20517/jtgg.2018.27 Page 13 of 15

consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiol Biomarkers Prev 2015;24:1121-9.
17. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, et al. Identification of 23 new prostate cancer susceptibility loci using
the iCOGS custom genotyping array. Nat Genet 2013;45:385-91.
18. Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, et al. A meta-analysis of genome-wide association studies to iden-
tify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013;22:408-15.
19. Mijuskovic M, Saunders EJ, Leongamornlert DA, Wakerell S, Whitmore I, et al. Rare germline variants in DNA repair genes and the angio-
genesis pathway predispose prostate cancer patients to develop metastatic disease. Br J Cancer 2018;119:96-104.
20. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, et al. Fine-mapping of prostate cancer susceptibility loci in a large
meta-analysis identifies candidate causal variants. Nat Commun 2018;9:2256.
21. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, et al. Association analyses of more than 140,000 men identify 63 new
prostate cancer susceptibility loci. Nat Genet 2018;50:928-36.
22. Muller H. Androgen-control therapy in carcinoma of prostate. Arch Chir Neerl 1949;1:77-88.
23. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, et al. Androgen receptors in endocrine-therapy-
resistant human prostate cancer. Int J Cancer 1991;48:189-93.
24. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al. Mutation of the androgen-receptor gene in metastatic androgen-indepen-
dent prostate cancer. N Engl J Med 1995;332:1393-8.
25. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, et al. Frequent detection of codon 877 mutation in the androgen re-
ceptor gene in advanced prostate cancers. Cancer Res 1994;54:2861-4.
26. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer
transcriptome. Oncogene 2005;24:3847-52.
27. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in
prostate cancer. Science 2005;310:644-8.
28. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in pros-
tate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-9.
29. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011-25.
30. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP. Antibody-based detection of ERG rearrangements in prostate core biop-
sies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 2012;136:935-46.
31. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Neoplasia 2010;12:590-8.
32. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, et al. Molecular characterization of TMPRSS2-ERG gene fusion in the
NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007;9:200-6.
33. Baker SJ, Reddy EP. Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis. Proc
Natl Acad Sci U S A 2013;110:14819-20.
34. Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy:
implications for fusion status and DSB repair. Clin Cancer Res 2013;19:5202-9.
35. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer
in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-88.
36. Kron KJ, Murison A, Zhou S, Huang V, Yamaguchi TN, et al. TMPRSS2-ERG fusion co-opts master transcription factors and activates
NOTCH signaling in primary prostate cancer. Nat Genet 2017;49:1336-45.
37. Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, et al. SPOP mutated/CHD1-deleted lethal prostate cancer and abiraterone sensi-
tivity. Clin Cancer Res 2018;24:5585-93.
38. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12
mutations in prostate cancer. Nat Genet 2012;44:685-9.
39. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate cancer.
Nature 2012;487:239-43.
40. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol
2003;1:E59.
41. Ren S, Peng Z, Mao JH, Yu Y, Yin C, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions,
cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 2012;22:806-21.
42. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, et al. Synthetic lethal targeting of PTEN mutant cells with PARP in-
hibitors. EMBO Mol Med 2009;1:315-22.
43. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid en-
dometrial cancer. Nat Rev Clin Oncol 2011;8:302-6.
44. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, et al. PTEN deficiency in endometrioid endometrial adenocarci-
nomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010;2:53ra75.
45. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, et al. PTEN loss compromises homologous recombination repair in astro-
cytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010;70:5457-64.
46. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient
cells independent of DNA DSB repair. Cell Cycle 2009;8:2198-210.
47. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51